Molecular Predictors of Response to Chemotherapy in Non-Small Cell Lung Cancer

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cancer Journal

• Publication date

  2011-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/PPO.0b013e318213f3cfPMID 21427554
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bevacizumab Plus Platinum-Based Chemotherapy

  2012cited by this paper
• New driver mutations in non-small-cell lung cancer.

  2011cited by this paper
• Genetically informed lung cancer medicine

  2011cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC).

  2010cited by this paper
• Significance of thymidylate synthase for resistance to pemetrexed in lung cancer

  2010cited by this paper
• ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial.

  2010cited by this paper
• Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer

  2010cited by this paper
• ERCC1, RRM1, and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.

  2010cited by this paper
• Low thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase mRNA expression correlate with prolonged survival in resected non-small-cell lung cancer.

  2010cited by this paper
• Prognostic factors in histopathology of lung cancer.

  2010cited by this paper
• Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

  2010cited by this paper
• Identification of thymidylate synthase as a potential therapeutic target for lung cancer

  2010cited by this paper
• Genetic Determinants of Pemetrexed Responsiveness and Nonresponsiveness in Non-small Cell Lung Cancer Cells

  2010cited by this paper
• Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.

  2009cited by this paper
• Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine.

  2009cited by this paper
• The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.

  2009cited by this paper
• Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.

  2009cited by this paper
• Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.

  2009cited by this paper
• Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.

  2009cited by this paper
• Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers.

  2009cited by this paper
• Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy.

  2009cited by this paper
• The revised TNM staging system for lung cancer.

  2009cited by this paper
• TS‐1 enhances the effect of radiotherapy by suppressing radiation‐induced hypoxia‐inducible factor‐1 activation and inducing endothelial cell apoptosis

  2008cited by this paper
• Thymidylate synthase in situ protein expression and survival in stage I nonsmall‐cell lung cancer

  2008cited by this paper
• Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine

  2008cited by this paper
• Characterization of Functional Excision Repair Cross-Complementation Group 1 Variants and Their Association with Lung Cancer Risk and Prognosis

  2008cited by this paper
• Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.

  2008cited by this paper
• Lung cancer.

  2008cited by this paper
• Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

  2008cited by this paper
• Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

  2008cited by this paper
• Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.

  2008cited by this paper
• Excision repair cross‐complementation group 1 predicts progression‐free and overall survival in non‐small cell lung cancer patients treated with platinum‐based chemotherapy

  2007cited by this paper
• ERCC1 mRNA Expression Is Not Associated with Response and Survival after Platinum-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer

  2007cited by this paper
• DNA repair and survival in lung cancer--the two faces of Janus.

  2007cited by this paper
• C3-06: ERCC1 expression as a predictive marker in stage IIIA, N2 positive non-small cell lung cancer patients treated with neoadjuvant concurrent chemoradiotherapy followed by surgery

  2007cited by this paper
• DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.

  2007cited by this paper
• Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.

  2007influential reference
• RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.

  2006cited by this paper
• Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.

  2006cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase

  2006cited by this paper
• ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.

  2006cited by this paper
• DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

  2006cited by this paper
• Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung

  2006cited by this paper
• Cellular pharmacology of gemcitabine.

  2006cited by this paper
• Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase.

  2006cited by this paper
• Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer.

  2005cited by this paper
• ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer.

  2005cited by this paper
• Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer.

  2005cited by this paper
• ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy.

  2005cited by this paper
• An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines

  2004cited by this paper
• Gene Expression as a Predictive Marker of Outcome in Stage IIB-IIIA-IIIB Non-Small Cell Lung Cancer After Induction Gemcitabine-Based Chemotherapy Followed By Resectional Surgery

  2004cited by this paper
• Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

  2004cited by this paper
• Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

  2004cited by this paper
• Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.

  2004cited by this paper
• A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10

  2004cited by this paper
• Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients

  2004cited by this paper
• Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.

  2003cited by this paper
• Surgical treatment of lung cancer. Past and present.

  2003cited by this paper
• 5-Fluorouracil: mechanisms of action and clinical strategies

  2003cited by this paper
• Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer

  2003cited by this paper
• Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer.

  2002cited by this paper
• Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung.

  2002cited by this paper
• Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

  2002cited by this paper
• Automated subcellular localization and quantification of protein expression in tissue microarrays

  2002cited by this paper
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002cited by this paper
• How nucleotide excision repair protects against cancer

  2001cited by this paper
• Genome maintenance mechanisms for preventing cancer

  2001cited by this paper
• Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.

  2000cited by this paper
• Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy.

  2000cited by this paper
• Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1)

  1999cited by this paper
• Thymidylate Synthase Protein and p53 mRNA Form an In Vivo Ribonucleoprotein Complex

  1999cited by this paper
• Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.

  1996cited by this paper
• DNA repair: enzymatic mechanisms and relevance to drug response.

  1996cited by this paper
• Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.

  1995cited by this paper
• Cisplatin and DNA repair in cancer chemotherapy.

  1995influential reference
• Thymidylate synthase and drug resistance.

  1995cited by this paper
• Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells.

  1995cited by this paper
• Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

  1995cited by this paper
• Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.

  1994cited by this paper
• Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3.

  1993cited by this paper
• Elevated expression of thymidylate synthase in doxorubicin resistant human non small cell lung carcinomas.

  1992cited by this paper
• Cancer statistics

  1989cited by this paper
• Lung cancer: a review.

  1975cited by this paper
• Oncotargets and Therapy Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Gemcitabine for the Treatment of Advanced Nonsmall Cell Lung Cancer

  year unknowncited by this paper

• Progress in Research of Nanotherapeutics for Overcoming Multidrug Resistance in Cancer

  2024cites this paper
• Serum exosomal hsa-circ-0004771 modulates the resistance of colorectal cancer to 5-fluorouracil via regulating miR-653/ZEB2 signaling pathway

  2023cites this paper
• MicroRNA-155 and cancer metastasis: Regulation of invasion, migration, and epithelial-to-mesenchymal transition.

  2023cites this paper
• Tumor-associated macrophages secret exosomal miR-155 and miR-196a-5p to promote metastasis of non-small-cell lung cancer

  2021cites this paper
• Tumor-Associated Macrophages Secret Exosomal miR-155 to Promote Metastasis of Non-Small-Cell Lung Cancer

  2020cites this paper
• Expression and prognostic significance of melatonin receptor MT1 in patients with gastric adenocarcinoma.

  2019cites this paper
• Sotetsuflavone suppresses invasion and metastasis in non-small-cell lung cancer A549 cells by reversing EMT via the TNF-α/NF-κB and PI3K/AKT signaling pathway

  2018cites this paper
• 44 – Frontline Systemic Therapy Options in Nonsmall Cell Lung Cancer

  2018cites this paper
• High Ki67 Expression has Prognostic Value in Surgically-Resected T3 Gastric Adenocarcinoma.

  2016cites this paper
• High Expression of IncRNA-PCNA-AS1 in Human Gastric Cancer and its Clinical Significances.

  2015cites this paper
• Biodegradable and Biocompatible Polymers‐Based Drug Delivery Systems for Cancer Therapy

  2015cites this paper
• Role of autophagy in the ω-3 long chain polyunsaturated fatty acid-induced death of lung cancer A549 cells.

  2015cites this paper
• Novel serum biomarkers for lung cancer early diagnosis and clinical outcome

  2014cites this paper
• Effects of chemotherapy on global gene expression in non-small cell lung cancer.

  2014cites this paper
• ω-3 polyunsaturated fatty acids inhibit the proliferation of the lung adenocarcinoma cell line A549 in vitro.

  2014cites this paper
• Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum‐based chemotherapy in advanced nonsmall‐cell lung cancer patients

  2014cites this paper
• Prognostic value of differential CCND1 expression in patients with resected gastric adenocarcinoma

  2014cites this paper
• Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer

  2014cites this paper
• Evidence of Clinical Utility: An Unmet Need in Molecular Diagnostics for Patients with Cancer

  2014cites this paper
• Reply to an analysis of human equilibrative nucleoside transporter‐1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross‐complementing gene‐1 expression in patients with resected pancreas adenocarcinoma: Implications for adjuvant treatment

  2013cites this paper
• CUG-binding protein 1 (CUGBP1) expression and prognosis of non-small cell lung cancer

  2013cites this paper
• Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: round robin test.

  2013cites this paper
• Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma

  2013cites this paper
• polyunsaturated fatty acids inhibit the proliferation of the lung adenocarcinoma cell line A 549 in vitro

  2013cites this paper
• Excision repair cross‐complementing gene‐1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter‐1 expression and prognostic value in biliary tract malignancy

  2013cites this paper
• An analysis of human equilibrative nucleoside transporter‐1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross‐complementing gene‐1 expression in patients with resected pancreas adenocarcinoma

  2013influential citation
• Epigenetic downregulation of RUNX3 by DNA methylation induces docetaxel chemoresistance in human lung adenocarcinoma cells by activation of the AKT pathway.

  2013cites this paper
• Messenger RNA and protein expression of thymidylate synthase and DNA repair genes in thymic tumors.

  2013cites this paper
• Simultaneous Multi-Antibody Staining in Non-Small Cell Lung Cancer Strengthens Diagnostic Accuracy Especially in Small Tissue Samples

  2013cites this paper
• Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS)

  2012cites this paper
• Lung Cancer-derived Galectin-1 Enhances Tumorigenic Potentiation of Tumor-associated Dendritic Cells by Expressing Heparin-binding EGF-like Growth Factor*

  2012cites this paper
• Translating genomic information into clinical medicine: Lung cancer as a paradigm

  2012cites this paper
• Current world literature.

  2012cites this paper
• SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling

  2012cites this paper
• Post-operative treatment with cisplatin and vinorelbine in Chinese patients with non-small cell lung cancer: a clinical prospective analysis of 451 patients.

  2012cites this paper
• Molecular profiling and personalized medicine: from the guest editor.

  2011cites this paper